Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

Rhythm Pharmaceuticals is supported by a strengthening clinical and commercial profile for setmelanotide, with the Phase 2 PWS update showing mean BMI reduction improving from -1.84% at 3 months to -3.06% at 6 months, 14 of 17 patients with BMI reductions, and 8 of 10 patients with moderate to severe baseline hyperphagia achieving a clinically meaningful HQ-CT improvement, alongside favorable body-composition and quality-of-life signals. The company’s outlook is further reinforced by early launch momentum in acquired HO, where it has already seen more than 150 patient start forms within the first 6 weeks, 110 unique prescribers, and ~20 new patient starts added organically per week, suggesting a path to meaningful U.S. and ex-U.S. adoption as reimbursement hurdles clear. With the business anchored by a first-in-class precision medicine in a category with limited direct competition, additional upside from a broad rare-disease opportunity across the U.S., Europe, and Japan, and a modeling framework that implies ~$25 million in 2026 U.S. revenue and more than $640 million of U.S. peak revenue, the fundamentals support a constructive long-term view despite execution, regulatory, and patent risks.

Rhythm Pharmaceuticals is facing a fundamentally challenging risk-reward profile because its valuation is still highly dependent on setmelanotide and other early-stage MC4R assets that remain exposed to clinical risk, where later-stage patients may not reproduce earlier efficacy or safety and new tolerability issues could still emerge. The company’s international growth narrative also looks uneven, as Japan’s Japanese HO cohort was small (n=8 Imcivree vs n=4 placebo) despite a clinically meaningful BMI reduction of -13% placebo-adjusted, and management still expects first Japanese patient revenue only in 2027 after reimbursement negotiations that follow approval, limiting near-term financial contribution. At the same time, the downside scenario already assumes only 70% probability of success for approved/derisked indications and just 5% for PWS, bivamelagon, and the platform, while stated risks include regulatory uncertainty, intellectual property risk, competition, safety signals, and long-term pricing pressure, all of which support a negative outlook.